Navigation Links
BioXpress Therapeutics SA to Partner the 2011 BIO International Convention

GENEVA, Switzerland, June 15, 2011 /PRNewswire/ -- BioXpress Therapeutics SA, a Swiss-based biotechnology company developing high-quality monoclonal antibody (MAb) biosimilars announced today representatives from the Company will be partnering at the 2011 BIO International Convention's One-on-One Partnering Meetings being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.  

BioXpress Therapeutics currently has 4 biosimilar monoclonal antibody drugs in development with an additional 14 in the pipeline.

Representatives available to discuss partnering opportunities include:  Dr. Cori Gorman and Dr. Curt Scribner.  Companies or individuals attending BIO 2011 can schedule meetings with BioXpress Therapeutics by visiting (registration required):  

BioXpress Therapeutics Partnering Schedule:
Monday, June 27 Business Forum  -  12:00 PM - 5:00 PM
Tuesday, June 28 Business Forum  -  7:00 AM – 6:00 PM
Wednesday, June 29 Business Forum  -  7:00 AM – 6:00 PM
Thursday, June 30 Business Forum  -  7:00 AM – 6:00 PM

Each BioXpress Therapeutics biosimilar MAb is developed under strict non-clinical and clinical guidelines as outlined in the European Medicines Agency's "Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies."   Furthermore, each BioXpress Therapeutics biosimilar goes through a complete analytical comparison to determine the product is similar to the innovator product.

Having the correct primary sequence is absolutely critical for a biosimilar to have similarity and comparability to the innovator drug. Typically, there are several sequences published for every marketed monoclonal antibody. To ensure BioXpress Therapeutics has identified the correct sequence, the Company has developed a proprietary database of protein sequences based on comprehensive analysis of literature and patent databases. All data entry and data analysis is done by the Company's team which consists of scientists who have been actively involved in making monoclonal antibody therapeutics since the early 1980s. As a result, the BioXpress scientific team is well-versed in the literature and groups who have developed many of the originator MAbs over the decades. Based on the data from the BioXpress database, the biosimilar protein is expressed and compared to the originator to ensure a valid sequence before moving the drug forward.

About BioXpress Therapeutics

BioXpress Therapeutics SA is a privately held biotechnology committed to developing and supplying the highest quality and cost-competitive biosimilar biologic API for unmet need indications such as cancer, inflammation and autoimmunity.  Headquartered in Geneva, Switzerland, BioXpress Therapeutics business is focused on developing unbranded monoclonal antibody (MAb and MAb-like) biosimilar drugs under strict European Medicines Agency (EMA) guidelines.

For more information visit

Media Contact

Robert Meister

SOURCE BioXpress Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings
2. Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index
3. Northwest Biotherapeutics Announces Change and Expansion of Management Team
4. Northwest Biotherapeutics Announces Series of Financing Arrangements
5. Healthpoint Biotherapeutics Acquires Regranex® Gel
6. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
7. Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
9. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
10. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
11. Nile Therapeutics to Transition to OTCQB Marketplace
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... November 24, 2015 SHPG ) announced today ... the Piper Jaffray 27 th Annual Healthcare Conference in ... 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/29/2015)...  Connected health pioneer, Joseph C. Kvedar , ... health and wellness, and the business opportunities that arise ... Internet of Healthy Things . Long before health ... Dr. Kvedar, vice president, Connected Health, Partners HealthCare, was ... care from the hospital or doctor,s office into the ...
Breaking Biology News(10 mins):